The company was founded in December 2012 and is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. With excellent innovative drug discovery capabilities, advanced biotechnology research and development, large-scale production technology throughout the entire industry chain, and a combination of drugs under development with great market potential, the company has great potential in tumor immunotherapy, as well as treatment of autoimmune diseases, chronic metabolic diseases, neurological diseases, and infectious diseases. The company is an innovation-driven biopharmaceutical company with complete industrial chain capabilities from discovery and development of innovative drugs, global clinical research, large-scale production to commercialization. Main products: The company's product pipeline covers five major treatment fields, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurological diseases, and infectious diseases. Among them, the company is currently selling a total of 3 drugs, nearly 30 products under development are in clinical trials, and more than 20 products are in the pre-clinical development stage. Corporate honors: “Zhangjiang Star” Leading Enterprise in the Zhangjiang National Independent Innovation Demonstration Zone”, “Leading Power: High-Quality Chinese Pharmaceutical Development Achievement Enterprise (2022)”, “High Quality Development of the Big Health Industry - Excellent Case of Informatization”, etc.
No Data